ReviewBiochemical pharmacology2020
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Review in Biochemical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and clinical outcomes of cardiac injury in patients with COVID-19: A systematic review and meta-analysis.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2021Pooled it
- The emerging role of calsequestrin 2: from calcium sensor and modulator to arrhythmia driver.Journal of physiology and biochemistry · 2026Review
- Long-Term Cardiovascular and Mortality Risk in Patients with Pre-Existing Arrhythmia Post-SARS-CoV-2 Infection.Diagnostics (Basel, Switzerland) · 2025Article
- Impact of pulmonary infection and antibiotic use on recurrent myocardial infarction in patients with myocardial infarction.Scientific reports · 2025Article
- Evaluation of myocardial work and exercise capacity in patients recovered from the severe form of COVID-19.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Associations Between Severe Influenza-Complicated Thromboembolism Events, Intensive Care Unit Stays and Mortality, and Associated Risk Factors: A Retrospective Cohort Study.Influenza and other respiratory viruses · 2024Article
- Coronavirus disease 2019-related myocarditis genes contribute to ECMO prognosis.BMC cardiovascular disorders · 2024Article
- Review
- Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.Journal of community hospital internal medicine perspectives · 2024Review
- Two Commercially Available Blood-Stabilization Reagents Serve as Potent Inactivators of Coronaviruses.Pathogens (Basel, Switzerland) · 2023Article
- Correlation of covid-19 and Guillain-Barré syndrome: A Mechanistic Perspective.Obesity medicine · 2023Review
- Cardiac Involvement in Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) in Poland.Biomedicines · 2023Article
- Major adverse cardiovascular events are associated with necroptosis during severe COVID-19.Critical care (London, England) · 2023Observational
- The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread.Immunity, inflammation and disease · 2023Review
- Necroptosis Drives Major Adverse Cardiovascular Events During Severe COVID-19.Research square · 2023Article
- Investigating autonomic nervous system dysfunction among patients with post-COVID condition and prolonged cardiovascular symptoms.Frontiers in medicine · 2023Article
- Electrocardiographic Features and Outcome: Correlations in 124 Hospitalized Patients With COVID-19 and Cardiovascular Events.Journal of cardiothoracic and vascular anesthesia · 2022Article
- Frontiers of COVID-19-related myocarditis as assessed by cardiovascular magnetic resonance.World journal of clinical cases · 2022Review
- SARS-CoV2 Infection and Comorbidities, Role in Oncogenesis.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- New-Onset Dementia Among Survivors of Pneumonia Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.Open forum infectious diseases · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19), elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is a pandemic public health emergency of global concern. Other than the profound severe pulmonary damage, SARS-CoV-2 infection also leads to a series of cardiovascular abnormalities, including myocardial injury, myocarditis and pericarditis, arrhythmia and cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, and coagulation abnormalities. Meanwhile, COVID-19 patients with preexisting cardiovascular diseases are often at a much higher risk of increased morbidity and mortality. Up-to-date, a number of mechanisms have been postulated for COVID-19-associated cardiovascular damage including SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) activation, cytokine storm, hypoxemia, stress and cardiotoxicity of antiviral drugs. In this context, special attention should be given towards COVID-19 patients with concurrent cardiovascular diseases, and special cardiovascular attention is warranted for treatment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.